Wednesday, May 04, 2022 4:02:30 PM
Article on NervGen is out,https://ceo.ca/@geodan/nervgen-regenerates-neurons-what-is-a-drug-that-reverses-paralysis-ms-stroke-and-alzheimers-worth
NervGen Regenerates Neurons, What Is A Drug That Reverses Paralysis, MS, Stroke And Alzheimer's Worth?
Summary
NervGen has already regenerated neurons under the microscope and in live rats with severed spinal cords. The rats regained most of the function in paralyzed legs.
The market cap of NervGen is under $80 million. It is currently in Phase 1 FDA trials in humans and is about to go into Phase 2.
NervGen has exclusive rights to the technology from Case Western University. It is backed by top experts in the field and staffed by very high-level pharma executives.
It has no competitors that can repair damage to the nervous system. If it works 50% as well in humans as in animals, a $15 billion market cap is feasible.
I have it on CEO now, it is non exclusive, will put on Seeking Alpha later. Please spread it around. Thanks!
NervGen Regenerates Neurons, What Is A Drug That Reverses Paralysis, MS, Stroke And Alzheimer's Worth?
Summary
NervGen has already regenerated neurons under the microscope and in live rats with severed spinal cords. The rats regained most of the function in paralyzed legs.
The market cap of NervGen is under $80 million. It is currently in Phase 1 FDA trials in humans and is about to go into Phase 2.
NervGen has exclusive rights to the technology from Case Western University. It is backed by top experts in the field and staffed by very high-level pharma executives.
It has no competitors that can repair damage to the nervous system. If it works 50% as well in humans as in animals, a $15 billion market cap is feasible.
I have it on CEO now, it is non exclusive, will put on Seeking Alpha later. Please spread it around. Thanks!
Recent NGEN News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/27/2026 04:15:14 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 08:35:19 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 05/26/2026 08:30:34 PM
- Form F-X - Appointment of Agent for Service of Process and Undertaking • Edgar (US Regulatory) • 05/26/2026 01:40:03 PM
- Form F-10 - Registration Statement for Securities of certain Canadian Issuers. • Edgar (US Regulatory) • 05/26/2026 01:26:25 PM
- NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study • GlobeNewswire Inc. • 05/26/2026 11:15:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/22/2026 09:24:31 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 05/22/2026 09:20:13 PM
- NervGen Announces Pricing of US$60.0 Million Public Offering of Securities • GlobeNewswire Inc. • 05/22/2026 03:27:00 AM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 05/21/2026 08:34:51 PM
- NervGen Announces Proposed Public Offering of Securities • GlobeNewswire Inc. • 05/21/2026 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 08:19:44 PM
- NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/18/2026 11:15:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2026 08:28:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 08:06:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 09:05:57 PM
- NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer • GlobeNewswire Inc. • 04/27/2026 11:30:00 AM
- NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference • GlobeNewswire Inc. • 04/13/2026 11:45:00 AM
- NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/31/2026 11:45:00 AM
- Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] • Edgar (US Regulatory) • 03/31/2026 11:30:34 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/13/2026 09:04:36 PM
- NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange • GlobeNewswire Inc. • 03/12/2026 08:15:00 PM
- NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs • GlobeNewswire Inc. • 03/04/2026 12:30:00 PM
- NervGen Pharma to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/18/2026 12:30:00 PM
